{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:10:25Z","timestamp":1790478625557,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10773-1","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:02:49Z","timestamp":1742486569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Wei","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"4","key":"10773_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","volume":"56","author":"M Zeng","year":"2023","unstructured":"Zeng M, Xia J, Zong Z, Shi Y, Ni Y, Hu F, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect. 2023;56(4):653\u201371. https:\/\/doi.org\/10.1016\/j.jmii.2023.01.017.","journal-title":"J Microbiol Immunol Infect"},{"key":"10773_CR2","doi-asserted-by":"publisher","first-page":"1385118","DOI":"10.3389\/fpubh.2024.1385118","volume":"12","author":"K Sun","year":"2024","unstructured":"Sun K, Peng F, Xu K, Liu Y, Zhou X, Shang N, Li C. A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistant acinetobacter baumannii ventilator-associated pneumonia. Front Public Health. 2024;12:1385118. https:\/\/doi.org\/10.3389\/fpubh.2024.1385118.","journal-title":"Front Public Health"},{"key":"10773_CR3","unstructured":"CHINET. Results of bacterial resistance surveillance in 2023 [updated 2024-03-05. https:\/\/www.chinets.com\/Document\/Index?pageIndex=0#"},{"key":"10773_CR4","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of America 2024 guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"7","key":"10773_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1039\/c7np00023e","volume":"34","author":"F Rabanal","year":"2017","unstructured":"Rabanal F, Cajal Y. Recent advances and perspectives in the design and development of polymyxins. Nat Prod Rep. 2017;34(7):886\u2013908. https:\/\/doi.org\/10.1039\/c7np00023e.","journal-title":"Nat Prod Rep"},{"issue":"1","key":"10773_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12879-023-08339-0","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang J, Shah BK, Zhao J, Xiong J, Wang C, Xie S. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect Dis. 2023;23(1):351. https:\/\/doi.org\/10.1186\/s12879-023-08339-0.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10773_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3855\/jidc.18887","volume":"18","author":"D Liu","year":"2024","unstructured":"Liu D, Jie F, Ding Y, Qu H, Chen D, Huang J. Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB. J Infect Dev Ctries. 2024;18(7):1050\u20137. https:\/\/doi.org\/10.3855\/jidc.18887.","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"10773_CR8","doi-asserted-by":"publisher","first-page":"107273","DOI":"10.1016\/j.ijantimicag.2024.107273","volume":"64","author":"X Yang","year":"2024","unstructured":"Yang X, Wang T, Zhang B, Zhang W, Wu G, Xu D, et al. Clinical outcome assessment of colistin sulphate in children with carbapenem-resistant organism infections: first data from China. Int J Antimicrob Agents. 2024;64(3):107273. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107273.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10773_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40121-023-00909-8","volume":"13","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jiang S, Li D, Wu Y, Li Q, Wang X, et al. Clinical efficacy and safety of colistin sulfate in the treatment of Carbapenem-Resistant organism infections in patients with hematological diseases. Infect Dis Ther. 2024;13(1):141\u201354. https:\/\/doi.org\/10.1007\/s40121-023-00909-8.","journal-title":"Infect Dis Ther"},{"key":"10773_CR10","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.2147\/IDR.S473200","volume":"17","author":"YC Ma","year":"2024","unstructured":"Ma YC, Sun YQ, Wu X, Wang YJ, Yang XL, Gu JJ. Clinical effectiveness and safety of colistin sulphate in treating infections caused by Carbapenem-Resistant organisms and analysis of influencing factors. Infect Drug Resist. 2024;17:3793\u2013804. https:\/\/doi.org\/10.2147\/IDR.S473200.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10773_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12890-022-02234-1","volume":"22","author":"R Zhang","year":"2022","unstructured":"Zhang R, Wu Y, Deng G, Deng J. Value of sputum gram stain, sputum culture, and Bronchoalveolar lavage fluid gram stain in predicting single bacterial pathogen among children with community-acquired pneumonia. BMC Pulm Med. 2022;22(1):427. https:\/\/doi.org\/10.1186\/s12890-022-02234-1.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10773_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","volume":"56","author":"AP Betrosian","year":"2008","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432\u20136. https:\/\/doi.org\/10.1016\/j.jinf.2008.04.002.","journal-title":"J Infect"},{"issue":"1","key":"10773_CR13","doi-asserted-by":"publisher","first-page":"e0245368","DOI":"10.1371\/journal.pone.0245368","volume":"16","author":"M Murali","year":"2021","unstructured":"Murali M, Suppes SL, Feldman K, Goldman JL. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children\u2019s hospital. PLoS ONE. 2021;16(1):e0245368. https:\/\/doi.org\/10.1371\/journal.pone.0245368.","journal-title":"PLoS ONE"},{"issue":"1","key":"10773_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204. https:\/\/doi.org\/10.1186\/cc11454.","journal-title":"Crit Care"},{"issue":"6","key":"10773_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver, Clinical Practice Guideline Panel","year":"2019","unstructured":"European Association for the Study of the Liver, Clinical Practice Guideline Panel. Chair, panel members, EASL governing board representative. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"issue":"4","key":"10773_CR16","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s40121-021-00524-5","volume":"10","author":"D Chen","year":"2021","unstructured":"Chen D, Qian Z, Su H, Meng Z, Lv J, Huang Y, et al. Invasive pulmonary aspergillosis in Acute-on-Chronic liver failure patients: Short-Term outcomes and antifungal options. Infect Dis Ther. 2021;10(4):2525\u201338. https:\/\/doi.org\/10.1007\/s40121-021-00524-5.","journal-title":"Infect Dis Ther"},{"key":"10773_CR17","doi-asserted-by":"publisher","unstructured":"Groft LM, Claeys KC, Heil EL. An evaluation of meropenem\/vaborbactam for the treatment of nosocomial pneumonia. Expert Opin Pharmacother. 2021;22(3):265\u2013\u200971. https:\/\/doi.org\/10.1080\/14656566.2020.1840552","DOI":"10.1080\/14656566.2020.1840552"},{"issue":"5","key":"10773_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3760\/cma.j.cn121430-20220516-00483","volume":"35","author":"L Lu","year":"2023","unstructured":"Lu L, Yang C, Zhu H, Sun K, Liu L, Duan S, Tang J. Regularity of ventilator-associated pneumonia induced by three common pathogens. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023;35(5):482\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn121430-20220516-00483. Chinese.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"4","key":"10773_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10773_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/phar.4601","volume":"44","author":"QJ Yang","year":"2024","unstructured":"Yang QJ, Xiang BX, Song MH, Yang CY, Liang JH, Xie YL, Zuo XC. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study. Pharmacotherapy. 2024;44(8):631\u201341. https:\/\/doi.org\/10.1002\/phar.4601.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10773_CR21","doi-asserted-by":"publisher","first-page":"107031","DOI":"10.1016\/j.ijantimicag.2023.107031","volume":"63","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Dong R, Huang Y, Ling X, Ye Z, Jiang S. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study. Int J Antimicrob Agents. 2024;63(1):107031. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107031.","journal-title":"Int J Antimicrob Agents"},{"key":"10773_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02324-8","author":"HH Zhuang","year":"2024","unstructured":"Zhuang HH, Qu Q, Long WM, Hu Q, Wu XL, Chen Y, et al. Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study. Infection. 2024. https:\/\/doi.org\/10.1007\/s15010-024-02324-8. Online ahead of print.","journal-title":"Infection"},{"key":"10773_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/IDR.S294282","volume":"14","author":"C Zhou","year":"2021","unstructured":"Zhou C, Jin L, Wang Q, Wang X, Chen F, Gao Y, et al. Bloodstream infections caused by Carbapenem-Resistant enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731\u201342. https:\/\/doi.org\/10.2147\/IDR.S294282.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"10773_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/antibiotics10050484","volume":"10","author":"W Katip","year":"2021","unstructured":"Katip W, Uitrakul S, Oberdorfer P. Short-Course versus Long-Course colistin for treatment of Carbapenem-Resistant A.baumannii in cancer patient. Antibiot (Basel). 2021;10(5):484. https:\/\/doi.org\/10.3390\/antibiotics10050484.","journal-title":"Antibiot (Basel)"},{"issue":"8","key":"10773_CR25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiph.2023.05.024","volume":"16","author":"W Katip","year":"2023","unstructured":"Katip W, Rayanakorn A, Oberdorfer P, Taruangsri P, Nampuan T. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study. J Infect Public Health. 2023;16(8):1249\u201355. https:\/\/doi.org\/10.1016\/j.jiph.2023.05.024.","journal-title":"J Infect Public Health"},{"issue":"4","key":"10773_CR26","first-page":"380","volume":"27","author":"M Papadimitriou-Olivgeris","year":"2019","unstructured":"Papadimitriou-Olivgeris M, Assimakopoulos SF, Kolonitsiou F, Solomou A, Vamvakopoulou S, Spyropoulou A, et al. Risk factors for acute kidney injury in critically ill patients with bacteraemia by carbapenem non-susceptible gram negative bacteria. Infez Med. 2019;27(4):380\u201392.","journal-title":"Infez Med"},{"issue":"3","key":"10773_CR27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bcp.15061","volume":"88","author":"L Han","year":"2022","unstructured":"Han L, Xu FM, Zhang XS, Zhang CH, Dai Y, Zhou ZY, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity. Br J Clin Pharmacol. 2022;88(3):1202\u201310. https:\/\/doi.org\/10.1111\/bcp.15061.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10773_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/jac\/dkae185","volume":"79","author":"MH Song","year":"2024","unstructured":"Song MH, Xiang BX, Yang CY, Lee CH, Yan YX, Yang QJ, et al. A pilot clinical risk model to predict polymyxin-induced nephrotoxicity: a real-world, retrospective cohort study. J Antimicrob Chemother. 2024;79(8):1919\u201328. https:\/\/doi.org\/10.1093\/jac\/dkae185.","journal-title":"J Antimicrob Chemother"},{"key":"10773_CR29","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.2147\/IDR.S468890","volume":"17","author":"L Li","year":"2024","unstructured":"Li L, Huang X, Liu J, Li C, Lin Z, Ren R, et al. Efficacy and safety factors related to plasma Concentration-Optimized polymyxin B therapy in treating Carbapenem-Resistant Gram-Negative bacterial infections in China. Infect Drug Resist. 2024;17:3057\u201371. https:\/\/doi.org\/10.2147\/IDR.S468890.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10773_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pcmr.12468","volume":"29","author":"KP Mattos","year":"2016","unstructured":"Mattos KP, Lloret GR, Cintra ML, Gouv\u00eaa IR, Betoni TR, Mazzola PG, Moriel P. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigment Cell Melanoma Res. 2016;29(3):388\u201390. https:\/\/doi.org\/10.1111\/pcmr.12468.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10773_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jcpt.12543","volume":"42","author":"KPH Mattos","year":"2017","unstructured":"Mattos KPH, Cintra ML, Gouv\u00eaa IR, Ferreira L\u00c1, Velho PENF, Moriel P. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. J Clin Pharm Ther. 2017;42(5):573\u20138. https:\/\/doi.org\/10.1111\/jcpt.12543.","journal-title":"J Clin Pharm Ther"},{"issue":"6 Suppl 1","key":"10773_CR32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jn\/137.6.1586S","volume":"137","author":"JD Kopple","year":"2007","unstructured":"Kopple JD. Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr. 2007;137(6 Suppl 1):1586. https:\/\/doi.org\/10.1093\/jn\/137.6.1586S. S-1590S; discussion 1597S-1598S.","journal-title":"J Nutr"},{"issue":"0","key":"10773_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5604\/17322693.1208033","volume":"70","author":"Z Rzepka","year":"2016","unstructured":"Rzepka Z, Buszman E, Beberok A, Wrze\u015bniok D. From tyrosine to melanin: signaling pathways and factors regulating melanogenesis. Postepy Hig Med Dosw (Online). 2016;70(0):695\u2013708. https:\/\/doi.org\/10.5604\/17322693.1208033.","journal-title":"Postepy Hig Med Dosw (Online)"}],"updated-by":[{"DOI":"10.1186\/s12879-025-10859-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10773-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:48:58Z","timestamp":1743713338000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10773"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10773-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-025-10859-w","URL":"https:\/\/doi.org\/10.1186\/s12879-025-10859-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the Second Affiliated Hospital of Xi\u2019an Jiaotong University (No. 2024\u2009\u2212\u2009185). Given the retrospective nature of this research, the requirement for written informed consent was also waived by the Ethics Committee of the Second Affiliated Hospital of Xi\u2019an Jiaotong University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}